MOTS-c vs BPC-157
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
MOTS-c
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a mitochondrial-derived peptide that plays a key role in metabolic regulation and has emerged as a significant longevity research target.
Full details →BPC-157
Body Protection Compound-157 is a synthetic peptide derived from a protein found in human gastric juice. It has shown remarkable healing properties in research studies.
Full details →Side-by-Side Comparison
| Aspect | MOTS-c | BPC-157 |
|---|---|---|
| Mechanism | Activates AMPK pathway, enhances glucose uptake in skeletal muscle, improves insulin sensitivity, and regulates mitochondrial function. Acts as a metabolic hormone affecting whole-body energy homeostasis. | BPC-157 works through multiple pathways including upregulation of growth factor expression, nitric oxide system modulation, and promotion of angiogenesis. It enhances tendon-to-bone healing and supports the formation of new blood vessels. |
| Typical Dosage | Research protocols typically use 5-10mg administered subcutaneously several times per week. Optimal dosing not yet established. | Typical research dosages range from 250-500mcg administered 1-2 times daily. Both subcutaneous and oral administration have been studied. |
| Administration | Subcutaneous injection. Often combined with exercise protocols as it enhances exercise capacity and metabolic adaptation. | Can be administered subcutaneously near the injury site or systemically. Stable in gastric juice, making oral administration viable. |
| Side Effects | Limited human data. Animal studies show good tolerability. May affect energy levels and exercise performance. | Generally well-tolerated in research. Some reports of mild nausea or dizziness at higher doses. |
| Best For |
What They Have in Common
Both MOTS-c and BPC-157 are commonly used for: